EU/3/17/1908: Orphan designation for the treatment of retinitis pigmentosa

Recombinant truncated N-terminal fragment of human lens epithelium-derived growth factor

Overview

On 23 August 2017, orphan designation (EU/3/17/1908) was granted by the European Commission to Dorian Regulatory Affairs BV, the Netherlands, for recombinant truncated N-terminal fragment of human lens epithelium-derived growth factor for the treatment of retinitis pigmentosa.

Key facts

Active substance
Recombinant truncated N-terminal fragment of human lens epithelium-derived growth factor
Medicine name
-
Intended use
Treatment of retinitis pigmentosa
Orphan designation status
Withdrawn
EU designation number
EU/3/17/1908
Date of designation
23/08/2017
Sponsor
Dorian Regulatory Affairs BV
Soestdijkerstraatweg 7
1213 VP Hilversum
The Netherlands
Tel. +31 35 622 19 34
Fax +31 35 623 06 59
E-mail: info@dorian.nl

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Update history

DateUpdate
August 2022Please note that this product was withdrawn from the Union Register of orphan medicinal products in August 2022 on request of the Sponsor.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating